How should we use convalescent plasma therapies for the management of COVID-19?
Convalescent plasma (CP) from blood donors with antibodies to severe acute respiratory syndrome coronavirus 2 may benefit patients with COVID-19 by providing immediate passive immunity via transfusion or by being used to manufacture hyperimmune immunoglobulin preparations. Optimal product characteri...
| Main Authors: | , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
American Society of Hematology
2020
|
| _version_ | 1797107163807612928 |
|---|---|
| author | Wood, EM Estcourt, LJ McQuilten, ZK |
| author_facet | Wood, EM Estcourt, LJ McQuilten, ZK |
| author_sort | Wood, EM |
| collection | OXFORD |
| description | Convalescent plasma (CP) from blood donors with antibodies to severe acute respiratory syndrome coronavirus 2 may benefit patients with COVID-19 by providing immediate passive immunity via transfusion or by being used to manufacture hyperimmune immunoglobulin preparations. Optimal product characteristics (including neutralizing antibody titers), transfusion volume, and administration timing remain to be determined. Preliminary COVID-19 CP safety data are encouraging, but establishing the clinical efficacy of CP requires an ongoing international collaborative effort. Preliminary results from large, high-quality randomized trials have recently started to be reported. |
| first_indexed | 2024-03-07T07:12:07Z |
| format | Journal article |
| id | oxford-uuid:516906fe-c47a-47ab-856b-143d7d4f2f32 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T07:12:07Z |
| publishDate | 2020 |
| publisher | American Society of Hematology |
| record_format | dspace |
| spelling | oxford-uuid:516906fe-c47a-47ab-856b-143d7d4f2f322022-06-30T10:43:31ZHow should we use convalescent plasma therapies for the management of COVID-19?Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:516906fe-c47a-47ab-856b-143d7d4f2f32EnglishSymplectic ElementsAmerican Society of Hematology2020Wood, EMEstcourt, LJMcQuilten, ZKConvalescent plasma (CP) from blood donors with antibodies to severe acute respiratory syndrome coronavirus 2 may benefit patients with COVID-19 by providing immediate passive immunity via transfusion or by being used to manufacture hyperimmune immunoglobulin preparations. Optimal product characteristics (including neutralizing antibody titers), transfusion volume, and administration timing remain to be determined. Preliminary COVID-19 CP safety data are encouraging, but establishing the clinical efficacy of CP requires an ongoing international collaborative effort. Preliminary results from large, high-quality randomized trials have recently started to be reported. |
| spellingShingle | Wood, EM Estcourt, LJ McQuilten, ZK How should we use convalescent plasma therapies for the management of COVID-19? |
| title | How should we use convalescent plasma therapies for the management of COVID-19? |
| title_full | How should we use convalescent plasma therapies for the management of COVID-19? |
| title_fullStr | How should we use convalescent plasma therapies for the management of COVID-19? |
| title_full_unstemmed | How should we use convalescent plasma therapies for the management of COVID-19? |
| title_short | How should we use convalescent plasma therapies for the management of COVID-19? |
| title_sort | how should we use convalescent plasma therapies for the management of covid 19 |
| work_keys_str_mv | AT woodem howshouldweuseconvalescentplasmatherapiesforthemanagementofcovid19 AT estcourtlj howshouldweuseconvalescentplasmatherapiesforthemanagementofcovid19 AT mcquiltenzk howshouldweuseconvalescentplasmatherapiesforthemanagementofcovid19 |